Smoking is Down, Gyms are Full — So Why is the Nation's Health Still Stalling?

Smoking — What Actually Changed

The UK's progress on smoking is one of the genuine public health success stories of the last two decades. In 2024, 10.4% of adults in England smoked — down from 19.8% in 2011, a near-halving in just over a decade. The UK approach — tax rises, plain packaging, indoor bans, and a deliberately permissive attitude towards vaping as a harm reduction tool — has produced a measurable dividend. Cardiovascular deaths attributable to smoking have fallen. Lung cancer rates in older cohorts are declining.

But the vaping picture is unresolved. Around 10% of UK adults now vape, with daily use rising fastest among 25 to 49 year olds. The long-term health consequences are still genuinely unknown.

The Gym Paradox

The UK fitness industry reached a record 16.9% membership penetration rate in 2024 — around 11.5 million members — with revenue exceeding £5.7 billion and over 600 million individual gym visits recorded across the year. And yet obesity rates have not fallen. The WHO projects UK obesity prevalence reaching 35% by 2030. Physical inactivity still costs the NHS an estimated £900 million annually and the broader economy £7.4 billion each year.

A study published in Nature Health found that despite two decades of policy progress on physical activity promotion across 200 countries, global inactivity levels have remained broadly unchanged. The gym industry's honest answer is that they serve the already-motivated. Membership is highest among younger adults, people with higher incomes, and people who are already reasonably active. The populations carrying the greatest burden of preventable disease — older adults, lower socioeconomic groups, people from minority backgrounds — remain significantly underrepresented.

GLP-1 Drugs — Genuine Breakthrough or Very Expensive Sticking Plaster?

Semaglutide and tirzepatide have produced weight loss outcomes no lifestyle intervention has come close to matching at population scale. A UCL-led analysis published in The Lancet in October 2025 found that cardiovascular protection was largely independent of how much weight participants actually lost — suggesting semaglutide is acting directly on the mechanisms of cardiometabolic disease rather than purely as a consequence of weight reduction. That is a significant finding. These are not simply weight loss tools. They appear to be cardiometabolic medicines with weight loss as one of several clinical effects.

Real-world persistence data shows roughly half of patients discontinued within a year — though this is improving, with 63% of those starting in early 2024 still on treatment twelve months later. The harder question is whether we are medicalising what is fundamentally a structural problem — food environments designed around ultra-processed convenience, sedentary work patterns, cities built for cars rather than people.

The Structural Conclusion

The data across these three stories points to the same conclusion. The interventions that work tend to work for people who are already in a position to benefit from them — financially, geographically, informationally. Smoking prevalence in the most deprived areas of England is still nearly double that in the least deprived. Gym membership is heavily concentrated among higher income groups. GLP-1 drugs remain largely privately prescribed in the UK, with NHS access tightly constrained by clinical criteria, capacity, and cost.

This matters for anyone working in pharma or med-tech, because it directly shapes the commissioning environment. The question NHS commissioners are increasingly asking is not simply whether a product works in the trial population — but whether it works for the people who represent the greatest burden on the system, and whether it can be delivered in a way that reaches them. Products with compelling clinical data but a story that only applies to engaged, motivated, already-health-conscious patients will find it progressively harder to secure funding in a system told to address health inequalities as a statutory priority.

The five million annual deaths from inactivity are not in the gym. They are not filling in their GLP-1 prescription. They are not in any of the cohorts that lifestyle health interventions typically reach. That is the problem worth solving.